Three Antiparasitic Worm Medicines Scientists Are Studying for Cancer

Researched and Written by Keith Bishop, Clinical Nutritionist, Cancer Coach, Retired Pharmacist, Integrative Oncology Educator

You may have heard people talk about three medicines: fenbendazole, mebendazole, and ivermectin. All three were made to kill parasitic worms or bugs, not cancer. But scientists are now studying them to see if they can also fight cancer cells.

These three medicines are not the same. They work in different ways. This article explains what each one does, how they are alike, and how they are different — using easy words and short sentences.

This article will not tell you to take these drugs. It also won't tell you to avoid them. It just explains what scientists have found so far, in plain language.

What Do All Three Have in Common?

Fenbendazole and mebendazole come from the same drug family. They are both called "benzimidazoles," which is just a fancy word for a type of dewormer.

Ivermectin is different. It comes from a totally different family of drugs. It was discovered from a soil bacterium, and the scientist who found it won a Nobel Prize in 2015. [1]

Even though they come from different families, all three share one thing: they have been used safely for a long time, they are cheap, and they are easy to get. That is exactly why scientists got curious about them. [2]

That is where the similarities stop. Each drug fights cancer cells in its own way.

What Does Fenbendazole Do to Cancer Cells?

Fenbendazole is only approved for animals in the U.S., not people. Most of what we know about it and cancer comes from lab dishes and animal studies — not studies in people yet.

Here is what scientists have found:

• Breaks the cell's "skeleton." Cells have tiny tube-like parts called microtubules that help them divide. Fenbendazole jams these tubes, which can stop cancer cells from splitting into new cells. [3][4]
• Turns on a "self-destruct" switch. Cells have a safety protein called p53. When it turns on, it can make a damaged cell delete itself. Studies show fenbendazole can turn this switch on in cancer cells. [4][5]
• Cuts off the cell's sugar supply. Cancer cells eat a lot of sugar for fuel. Fenbendazole appears to block the doors cancer cells use to pull in sugar. [3][4]
• May trigger a different kind of cell death. Newer studies found fenbendazole can cause a type of "messy" cell death (called pyroptosis) in breast cancer cells, which is different from the usual clean self-destruct process. [6]

What Does Mebendazole Do to Cancer Cells?

Mebendazole is approved in the U.S. and has more real-world use in cancer patients than fenbendazole, including one completed early-stage human study in people with stomach and gut cancers.

• Breaks the cell's "skeleton," just like fenbendazole. It jams the same tiny tubes inside cells, which can stop cancer cells from dividing. [8][9]
• Wakes up immune cells. Studies show mebendazole can switch certain immune cells into a more aggressive, cancer-fighting mode. [10]
• May block new blood vessels. Tumors need new blood vessels to grow bigger. Some research links mebendazole to slowing this process down. [2]
• Can cross into the brain. Mebendazole is small enough to pass through the brain's protective barrier, which is why scientists are especially interested in it for brain tumors. [2]

Fenbendazole vs. Mebendazole — Cousins, Not Twins

Since both drugs come from the same family, they share a main move — breaking the cell's inner "skeleton." But they are not identical. Fenbendazole's research leans more toward cutting off sugar and turning on the p53 self-destruct switch. Mebendazole research leans more toward waking up immune cells and blocking blood vessels—and it has more real human data behind it. [2][3][10]

What Does Ivermectin Do to Cancer Cells?

Ivermectin comes from a different drug family, so it fights cancer cells differently than the other two.

• Breaks down a "growth switch" protein. Ivermectin causes the cell to destroy a protein called PAK1, which cancer cells use to grow and spread. [11][12]
• Blocks a growth signal path. Cells send messages to each other using a signal path called Wnt/beta-catenin. Cancer cells often use this path to keep growing. Ivermectin can block that signal. [13][14]
• May slow down spreading. Studies in colon and breast cancer cells show ivermectin can slow cancer cells from moving and spreading to other parts of the body. [15]
• Can pause cell growth. Ivermectin has been shown to trigger a "pause" process called autophagy, where cancer cells stop growing instead of dying right away. [11][12]

How Are All Three Alike?

• All three can trigger cancer cells to die or stop growing, in lab and animal studies.
• In these early studies, all three seem to affect cancer cells more than normal, healthy cells.
• All three have a long history of being used safely as anti-parasite drugs.

None of the three have large human studies showing they treat cancer. Most of the proof so far comes from lab dishes and animals, with only a few small studies in people. [7][17]

How Are They Different?

• Fenbendazole and mebendazole mainly attack the cell's inner "skeleton." Ivermectin mainly shuts off growth-signal proteins.

Mebendazole and ivermectin are approved for people in the U.S. Fenbendazole is approved only for animals—which matters a lot when looking at how much human proof exists for each one. [2][16]

Mebendazole has the most real human data of the three, including one finished early-stage study. Ivermectin has many lab studies but fewer human cancer studies. Fenbendazole's evidence is almost entirely from lab and animal studies so far. [7]

Quick Comparison Chart

What We Still Don't Know

It's important to be honest here: most of what you just read comes from lab dishes and animal studies, not large studies in people. Promising lab results are a good reason for scientists to keep studying these drugs — but they are not the same as proof that these drugs treat cancer in people. [7][17]

None of this research says these three drugs should replace regular cancer treatment.

What This Means for You

If you've been trying to understand fenbendazole, mebendazole, and ivermectin, hopefully this cleared things up. They are not the same drug wearing three different name tags. Each one attacks cancer cells in its own way, and each one has a different amount of human proof behind it.

If you are thinking about how any of these might fit alongside your treatment, knowing the science is only part of the picture. Timing, other medicines you take, and how it all fits your plan matter just as much. That is exactly what I help people work through, one-on-one and inside the Prevail Compass™.

Ready to know exactly how this fits your protocol — not just the mechanism, but the timing and interactions that matter for you?

5 Supplement Mistakes Workshop 

5 Mistakes with Fenbendazole, Mebendazole & Ivermectin

The Prevail Compass™ — Your personalized guide through every decision in your cancer journey. Learn more →

Explore more:

Learning Center  |  POC Academy  |  Cancer Coaching  |  POC Podcast / YouTube  |  Podcast Playlist

Together—We Prevail Over Cancer!™

Prevail. Assess. Don't Guess.™

Fenbendazole Mebendazole Ivermectin Reference Sources

1. Liu J, Zhang K, Cheng L, Zhu H, Xu T. Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin. Drug Des Devel Ther. 2020;14:285-296. PMID: 32021111 https://pubmed.ncbi.nlm.nih.gov/32021111/ 
2. Guerini AE, Triggiani L, Maddalo M, et al. Mebendazole as a Candidate for Drug Repurposing in Oncology. Cancers (Basel). 2019;11(9):1284. PMID: 31480477 https://pubmed.ncbi.nlm.nih.gov/31480477/ 
3. Son DS, Lee ES, Adunyah SE. The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs. Immune Netw. 2020;20(4):e29. PMID: 32895616 https://pubmed.ncbi.nlm.nih.gov/32895616/ 
4. Duan Q, Liu Y, Rockwell S. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Sci Rep. 2018;8:11-926. https://www.nature.com/articles/s41598-018-30158-6 
5. Papasotiriou I. Teaching an old dog new tricks: The case of Fenbendazole. Cancer Treat Res Commun. 2022;32:100601. PMID: 35780728 https://pubmed.ncbi.nlm.nih.gov/35780728/ 
6. Pan T, Jin S, Huang X, et al. Fenbendazole induces pyroptosis in breast cancer cells through HK2/caspase-3/GSDME signaling pathway. Front Pharmacol. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12314287/ 
7. Rousseau B, et al. A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer. Sci Rep. 2021. https://www.nature.com/articles/s41598-021-88433-y 
8. Sasaki J, Ramesh R, Chada S, Gomyo Y, Roth JA, Mukhopadhyay T. The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Ther. 2002;1(13):1201-1209. PMID: 12479701 https://pubmed.ncbi.nlm.nih.gov/12479701/ 
9. Golla U, Patel S, Shah N, et al. From Deworming to Cancer Therapy: Benzimidazoles in Hematological Malignancies. Cancers (Basel). 2024;16(20):3454. https://pmc.ncbi.nlm.nih.gov/articles/PMC11506385/ 
10. Blom K, Senkowski W, Jarvius M, et al. The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation. Immunopharmacol Immunotoxicol. 2017;39(4):199-210. PMID: 28472897 https://pubmed.ncbi.nlm.nih.gov/28472897/ 
11. Dou Q, Chen HN, Wang K, et al. Ivermectin Induces Cytostatic Autophagy by Blocking the PAK1/Akt Axis in Breast Cancer. Cancer Res. 2016;76(15):4457-4469. PMID: 27302166 https://pubmed.ncbi.nlm.nih.gov/27302166/ 
12. Wang K, Gao W, Dou Q, et al. Ivermectin induces PAK1-mediated cytostatic autophagy in breast cancer. Autophagy. 2016;12(12):2498-2499. PMID: 27657889 https://pubmed.ncbi.nlm.nih.gov/27657889/ 
13. Melotti A, Mas C, Kuciak M, Lorente-Trigos A, Borges I, Ruiz i Altaba A. The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer. EMBO Mol Med. 2014. PMID: 25143352 https://pubmed.ncbi.nlm.nih.gov/25143352/ 
14. Tang M, Hu X, Wang Y, et al. Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacol Res. 2021;163:105207. PMID: 32971268 https://pubmed.ncbi.nlm.nih.gov/32971268/ 
15. Jiang L, Sun YJ, Song XH, et al. Ivermectin inhibits tumor metastasis by regulating the Wnt/beta-catenin/integrin beta1/FAK signaling pathway. Am J Cancer Res. 2022;12(10):4502-4519. PMID: 36381328 https://pubmed.ncbi.nlm.nih.gov/36381328/ 
16. Hashimoto H, Messerli SM, Sudo T, Maruta H. Ivermectin inactivates the kinase PAK1 and blocks the PAK1-dependent growth of human ovarian cancer and NF2 tumor cell lines. Drug Discov Ther. 2009;3(6):243-246. PMID: 22495656 https://pubmed.ncbi.nlm.nih.gov/22495656/ 
17. Robalino KN, Vivanco-Galvan O, Romero-Benavides JC, Jimenez-Gaona Y. Ivermectin as an Alternative Anticancer Agent: A Review of Its Chemical Properties and Therapeutic Potential. Pharmaceuticals (Basel). 2025;18(10):1459. https://pmc.ncbi.nlm.nih.gov/articles/PMC12566834/ 

These statements have not been evaluated by the Food and Drug Administration. This content is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. It is not a substitute for medical advice. Always consult your licensed healthcare provider before starting, stopping, or changing any treatment or protocol.

© 2026 Keith Bishop, Prevail Over Cancer LLC. All rights reserved.